ArticleBMJ public health2025
Generic competition and price developments in the USA, Germany and Switzerland (2007-2023): a longitudinal observational study.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug expenditure has increased over the past years in the USA and Europe, mainly driven by originator drugs. Generic drugs have a substantial cost-saving potential. We analysed the number of generic competitors entering the market over time, distribution of market share between originator drugs and their generic competitors and association between the number of generic competitors and price changes of originator and generic drugs in the USA, Germany and Switzerland. Methods: In this longitudinal observational study, we included all originator drugs and their corresponding generic competitors with market entry between 2007 and 2023 in the USA, Germany and Switzerland from the IQVIA database. We extracted quarterly price and sales volume data for the same study period from the IQVIA database. Descriptive statistics and regression analyses were conducted to answer the research questions. Results: 530 active substances in the USA, 406 in Germany and 108 in Switzerland were included. 3 years after competition start, an average of four generic competitors entered the market in the USA, 7.6 in Germany and 3.3 in Switzerland. An increase in the number of generic competitors was associated with an increase in average generic market share. On average, the generic market share reached 90% after the entry of five generic drugs in the USA and nine in Germany, and was not reached in Switzerland. An association between the number of competitors and relative price decrease of generic drugs was observed in all three countries. This association was also observed for originator drugs in Switzerland and Germany, but not in the USA. Conclusions: The findings indicate that policies targeting market entry and prices of generic drugs would be helpful in all three countries. More research is needed to assess the impact of previous and future policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.